Stockreport

Lundbeck to acquire Alder BioPharmaceuticals – a company committed to transforming migraine treatment and prevention – in a transaction valued at up to USD 1.95 billion net of cash

ALDER BIOPHARMACEUTICALS INC  (ALDR) 
Last alder biopharmaceuticals inc earnings: 8/6 04:07 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.alderbio.com/node/5806
PDF Enhances Lundbeck’s leading portfolio of brain disease therapies with Alder’s highly complementary intravenous (IV) therapy for migraine prevention, eptinezumabEptinezum [Read more]